Mumbai, February 3, 2026
Sun Pharma Advanced Research Company Ltd. (SPARC) announced that it has received a Priority Review Voucher linked to the approval of its drug Sezaby, marking a significant milestone in the company’s innovation-led growth strategy.
The receipt of the voucher strengthens SPARC’s ability to accelerate the development of its clinical pipeline and enhances strategic flexibility in advancing future drug applications.
Key Development and Strategic Significance
The Priority Review Voucher is a transferable asset that enables expedited review of a subsequent drug application, allowing companies to significantly reduce regulatory timelines for future therapies. Such vouchers are typically awarded for the successful development of treatments addressing rare pediatric conditions.SPARC indicated that it intends to use the voucher to fast-track its pipeline programs, aligning with its focus on addressing high unmet medical needs globally.
Management Commentary
Commenting on the development, Anil Raghavan, Chief Executive Officer of SPARC, said that the voucher represents a major achievement for the company and reflects its commitment to delivering meaningful therapies for patients with urgent medical needs. He added that the recognition not only underscores the therapeutic value of Sezaby but also provides SPARC with added strategic options to bring new treatments to market faster.About Sezaby
Sezaby is a benzyl alcohol and propylene glycol-free formulation of phenobarbital sodium powder for injection. It has been approved for the treatment of neonatal seizures, addressing a critical requirement in pediatric care where formulation safety and efficacy are paramount.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.